Proton pump inhibitors (PPIs) increases risk of progression of chronic kidney disease (CKD) possibly due to tubulointerstitial nephritis. However, sparse data are demonstrated the evidence of tubulointerstitial damage. A novel biomarker of structural changes in tubular cells such as liver-type fatty acid binding protein (L-FABP), is used as a predictor of CKD progression by some researchers. We hypothesized that changing of urinary L-FABP due to interstitial fibrosis can predict the progression of CKD in patients with prolong used of PPIs.
